{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:44:19Z","timestamp":1792269859756,"version":"4.4.0"},"reference-count":2,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.eprac.2026.09.012","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:19:58Z","timestamp":1790608798000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Response to: From Glycemic Response to Clinical Trajectories: Extending Phenotyping in GLP-1RA-SGLT2 Inhibitor Combination Therapy"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1536-5697","authenticated-orcid":false,"given":"Agostino","family":"Milluzzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Frittitta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eprac.2026.09.012_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.eprac.2026.06.006","article-title":"Effectiveness of GLP-1 receptor agonists and SGLT-2 inhibitors combination therapy in type 2 diabetes: a real-world experience","author":"Milluzzo","year":"2026","journal-title":"Endocr Pract"},{"key":"10.1016\/j.eprac.2026.09.012_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.eprac.2026.08.022","article-title":"From glycaemic response to clinical trajectories: extending phenotyping in GLP-1RA-SGLT2 inhibitor combination therapy","author":"Corrao","year":"2026","journal-title":"Endocr Pract"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26011560?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26011560?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:03:23Z","timestamp":1792267403000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X26011560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":2,"alternative-id":["S1530891X26011560"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2026.09.012","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Response to: From Glycemic Response to Clinical Trajectories: Extending Phenotyping in GLP-1RA-SGLT2 Inhibitor Combination Therapy","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2026.09.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2026.08.022","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 AACE. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}